French Institute of Health and Medical Research

Paris, France

French Institute of Health and Medical Research

Paris, France
SEARCH FILTERS
Time filter
Source Type

Patent
Lille 2 University of Health, Law, French Institute of Health, Medical Research and Lille University Hospital Center | Date: 2015-06-11

The invention relates to compounds of formula (I) or the pharmaceutically acceptable solvates thereof, as well as to the use thereof as a drug.


Patent
Vaiomer, French Institute of Health and Medical Research | Date: 2017-05-31

The present invention concerns polydextrose for use for preventing and/or treating heart failure in a subject.


Patent
Agv Discovery, French Institute of Health, Medical Research, French National Center for Scientific Research and Montpellier University | Date: 2017-05-24

The present invention concerns a compound of formula (I):


Patent
French Institute of Health, Medical Research and Assistance Publique Hopitaux De Paris | Date: 2017-06-14

The invention relates to the field of immunology and cell therapy. The invention relates to an in vitro or ex vivo method for obtaining hematopoietic cell population containing regulatory T cells (Tregs) specific for an irrelevant antigen, to a hematopoietic cell population obtained by said method, to a pharmaceutical composition and a product containing said hematopoietic cell population and therapeutic use thereof.


Patent
Aix - Marseille University, French Institute of Health and Medical Research | Date: 2017-06-14

The present invention relates to an in vitro method for the prognosis and/or diagnosis of a pancreatic cancer comprising the detection of a BSDL gene with an apparent cytosine insertion in a patient sample.


Patent
French Institute of Health, Medical Research, University of Lorraine, Nancy University Hospital Center, University Paris Diderot and University of Paris Descartes | Date: 2017-01-31

The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.


Patent
Ose Immunotherapeutics, French Institute of Health and Medical Research | Date: 2017-01-26

The invention relates to recombinant monovalent antibodies which are heterodimers of a first protein chain comprising the variable domain of the heavy chain of an antibody of interest and the CH2 and CH3 domains of an IgG immunoglobulin and a second protein chain comprising the variable domain of the light chain of said immunoglobulin of interest and the CH2 and CH3 domains of said IgG immunoglobulin. These antibodies can be used in particular as therapeutic agents in all cases where monovalent binding to a ligand such a cellular receptor is required.


Patent
French Institute of Health, Medical Research, Aix - Marseille University, Institute Jean Paoli & Irene Calmettes and French National Center for Scientific Research | Date: 2017-02-08

The present invention relates to methods for selecting binders by phage display and masked selection. More particularly, the present invention relates to a method for selecting a plurality of binders specific for at least one relevant target comprising screening a phage binder library of binders against the relevant target in presence of a plurality of binders obtained from a library of binders directed against at least one irrelevant target and positively selecting the binders that are specific for the at least one relevant target.


Patent
Institute Pasteur Paris, French Institute of Health, Medical Research and Assistance Publique Hopitaux De Paris | Date: 2017-04-19

A massive clonal expansion of activated CD8^(+) T-cells with increased frequency of HPV 16-specific CD8^(+) T-cells was discovered to be a characteristic of oral lichen planus (OLP), indicating a causal link between HPV infection and the dysimmune process. The invention relates to compositions and methods for the diagnosis and treatment of OLP patients.


Rasika S.,French Institute of Health and Medical Research
Nature Neuroscience | Year: 2016

A sparse population of a few hundred primarily hypothalamic neurons forms the hub of a complex neuroglial network that controls reproduction in mammals by secreting the 'master molecule' gonadotropin-releasing hormone (GnRH). Timely postnatal changes in GnRH expression are essential for puberty and adult fertility. Here we report that a multilayered microRNA-operated switch with built-in feedback governs increased GnRH expression during the infantile-to-juvenile transition and that impairing microRNA synthesis in GnRH neurons leads to hypogonadotropic hypogonadism and infertility in mice. Two essential components of this switch, miR-200 and miR-155, respectively regulate Zeb1, a repressor of Gnrh transcriptional activators and Gnrh itself, and Cebpb, a nitric oxide–mediated repressor of Gnrh that acts both directly and through Zeb1, in GnRH neurons. This alteration in the delicate balance between inductive and repressive signals induces the normal GnRH-fuelled run-up to correct puberty initiation, and interfering with this process disrupts the neuroendocrine control of reproduction. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

Loading French Institute of Health and Medical Research collaborators
Loading French Institute of Health and Medical Research collaborators